Predicting individual sensitivity of malignant melanoma to combination therapies by statistical and network modeling on innovative 3D organotypic screening models

SCHEME: INTER

CALL: 2013

DOMAIN: BM - Life Sciences, Biology and Medicine

FIRST NAME: Thomas

LAST NAME: Sauter

INDUSTRY PARTNERSHIP / PPP: No

INDUSTRY / PPP PARTNER:

HOST INSTITUTION: University of Luxembourg

KEYWORDS:

START: 2015-05-01

END: 2018-04-30

WEBSITE: https://www.uni.lu

Submitted Abstract

Despite remarkable efforts, metastatic melanoma still presents with significant mortality. Recently, mono-chemotherapies are increasingly replenished by more cancer specific combination therapies involving death ligands and drugs interfering with cellular life and death signaling. Still, metastatic melanoma remains a fatal disease because tumors rapidly develop resistance to novel therapies thereby regaining tumorigenic capacity. By combining statistical and network modeling and systems analysis with basic research and clinical data we aim to elucidate mechanisms of therapy-resistance of melanoma and to identify combinatorial systems biomarkers to prognosticate treatment responsiveness of BRAF mutated metastatic melanoma to BRAF (dabrafenib) /MEK (trametenib) inhibitors and to TRAIL death receptor agonists. Our proposal builds on a substantial amount of very promising preliminary data, and will set an example for how innovative systems-level strategies can be exploited to address urgent clinical needs for developing predictive assays for existing drugs and new drug combinations. The research team comprises academic, clinical and private partners, and provides the framework that is required for the integration of validated systems tools into clinical trials and clinical practice to benefit patients in the short term.

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement